Lowest Price Guaranteed
Pages
365
Last Updated
February 2026
View Count
20081
The next generation sequencing market size, valued at USD 8.6 billion in 2025, is projected to reach USD 9.8 billion in 2026 and USD 46.5 billion by 2035, with a 18.9% CAGR during the forecast period 2026 to 2035.
To learn more about this report, request a free sample copy
The new research study consists of industry trends, detailed market analysis of service providers and NGS technologies / platforms, technologies / platforms competitiveness analysis, patent analysis, clinical trial analysis, big pharma analysis, case study analysis and market impact analysis, along with market forecast and opportunity analysis.
 |
 |
 |
Next-generation sequencing is a new sequencing technology used for the sequencing of whole genomes to understand genetic variations associated with a wide range of diseases. The potential of sequencing entire genome simultaneously has brought unprecedented opportunities for research and diagnosis of diseases at molecular level.
The prevalence of chronic diseases has significantly increased over the years, raising serious concerns. According to the report of Centers for Disease Control and Prevention, nearly six out of 10 Americans are suffering from at least one chronic disease, indicating the growing risk of chronic diseases. In order to mitigate this concern, researchers are leveraging next-generation sequencing for analyzing diseases at molecular level through metagenomics studies. In addition to disease diagnosis, next-generation sequencing helps to design cell therapies, identify biomarkers and develop targeted therapies.
 |
 |
 |
Presently, the next-generation sequencing platforms have experienced limited adoption due to the high installation cost, requirement of skilled personnels and limited in-house infrastructure to implement NGS workflow. To address these concerns, several industry players (including Illumina and PacBio) are offering next-generation sequencing services. It is worth mentioning that outsourcing NGS solutions is cost-effective, reduces analysis time and provides accuracy in generating sequencing data.
The benefits offered by the outsourcing of next-generation sequencing have caught the attention of several government organizations and industrial players who are presently indulging in several national population genome mapping projects. Further, the next-generation technologies have shown high efficiency during clinical trials, owing to which the participation of volunteers in such trials has increased, thus helping the researchers in better decision making for the evaluated drug or technology.
 |
 |
 |
ith continuous research efforts and innovation in this field, it is anticipated that the adoption of these sequencing techniques will increase significantly, driving the next generation sequencing market growth during the forecast period, till 2035.
The market research report presents an in-depth analysis of the various next-generation sequencing companies across different segments, as defined in the table below:
| Key Report Attributes | Details | |
| Historical Trend | Since 2020 | |
| Forecast Period | Till 2035 | |
| Current Market Size | USD 9.8 Billion | |
| Market Size in 2035 | USD 46.5 Billion | |
| CAGR (Till 2035) | 18.9% | |
| Type of Component |
|
|
| Type of NGS Technique |
|
|
| Type of Technology Used |
|
|
| Application Area |
|
|
| Target Therapeutic Area |
|
|
| Purpose |
|
|
| End Users |
|
|
| Geographical Regions |
|
|
| Market in North America |
|
|
| Market in Europe |
|
|
| Market in Asia-Pacific |
|
|
| Market in Middle East and North Africa |
|
|
| Market in Latin America |
|
|
| Key Next Generation Sequencing Companies Profiled |
|
|
| Key Next-generation Sequencing Technology Providers Profiled |
|
|
| PowerPoint Presentation (Complimentary) |
Available | |
| Customization Scope | 15% Free Customization | |
| Excel Data Packs (Complimentary) |
|
|
One of the key objectives of this market report was to estimate the current market size, opportunity and the future growth potential of the market, over the forecast period. We have provided informed estimates on the likely evolution of the market for the forecast period.
The next generation sequencing market analysis also features the likely distribution of the current and forecasted opportunity within the next generation sequencing industry across various segments, such as type of component (consumables, services and instruments), type of NGS technique (targeted sequencing, whole genome sequencing / whole exome sequencing, RNA sequencing and other techniques), type of technology used (sequencing by synthesis technology, ion semiconductor technology, nanopore sequencing technology and other technologies), application area (clinical applications, and research and applied applications), target therapeutic area (oncological disorders, genetic disorders, reproductive disorders and other therapeutic areas), purpose (diagnosis, risk assessment, presymptomatic assessment,, screening and other purposes), end users (academic and research institutes, hospitals and clinics, pharmaceutical and biotechnology companies, and other end users) and geographical regions (North America, Europe, Asia-Pacific, Middle East and North Africa, and Latin America).
To account for the uncertainties associated with the next-generation sequencing and to add robustness to our model, we have provided three market forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.
Notably, all the actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this market report are in USD, unless otherwise specified.
This market report highlights the segmentation of the next generation sequencing market into consumables, services and instruments, based on type of component. Currently, the consumables segment captures the maximum share (67%) in the overall market and this trend is likely to remain unchanged in the future as well (CAGR of 18.7%). This can be attributed to the growing demand for consumables in research applications of next-generation sequencing.
This next generation sequencing market report highlights the segmentation of the market size into targeted sequencing, whole genome sequencing / whole exome sequencing, RNA sequencing and other techniques, based on the type of NGS technique. Currently, the targeted sequencing segment captures the maximum share (45%) in the overall market. However, whole genome sequencing / whole exome sequencing segment is expected to grow at a relatively higher CAGR (19.5%), during the forecast period, till 2035.
This market report highlights the segmentation of the market into sequencing by synthesis technology, ion semiconductor technology, nanopore sequencing technology and other technologies, based on the type of technology used. Currently, the sequencing by synthesis technology segment captures the maximum next generation sequencing market share (82%) and this trend is likely to remain unchanged in the future as well. However, nanopore sequencing technology segment is expected to grow at a relatively higher CAGR (20.5%), during the forecast period, till 2035.
The next generation sequencing market size is further divided into various sub-segments based on the application area, such as clinical applications, and research and applied applications. Currently, the clinical applications segment captures the maximum share (57%) in the overall market. This segment is expected to grow at a relatively higher CAGR (21.1%), during the forecast period, till 2035.
This segment highlights the distribution of market across various target therapeutic area such as, oncological disorders, genetic disorders, reproductive disorders and other therapeutic area. Currently, oncological disorders occupy the highest next generation sequencing market share (50%), and this trend is likely to remain unchanged. This can be attributed to the growing preference of next-generation sequencing technologies for early diagnosis and prevention of cancer at molecular level.
However, the other therapeutic areas segment is likely to grow at a relatively higher CAGR (26.6%) during the forecast period, till 2035.
The next generation sequencing market is further divided into various sub-segments based on the purpose such as diagnosis, risk assessment, presymptomatic assessment, screening and other purposes. Currently, the market is driven by the diagnosis segment (58%) in the overall market and this trend is likely to remain unchanged. However, other purposes segment is expected to grow at a relatively higher CAGR (20.1%), during the forecast period, till 2035.
The global market is segmented into different end users, including academic and research institutes, hospitals and clinics, pharmaceutical and biotechnology companies, and other end users. Currently, the academic and research institutes segment captures the maximum next generation sequencing market share (45%), and this trend is likely to remain unchanged in the future as well. This can be attributed to the heightened adoption of NGS services in oncological research and personalized medicine by various research institutions across the globe.
However, hospitals & clinics segment is anticipated to grow at a relatively higher CAGR (21.7%) during the forecast period, till 2035.
Next generation sequencing market analysis highlights the distribution of the market size across various geographies, such as North America, Europe and Asia-Pacific, Middle East and North Africa and Latin America. According to our projections, North America is likely to capture the majority (51%) of the current market share, and this trend is likely to remain unchanged in the future.
However, the market in Asia-Pacific is expected to grow at a relatively higher CAGR (20.6%), during the forecast period. This can be attributed to the increasing support from the government organizations for clinical research, increasing expenditure on the improvement of healthcare infrastructure and rising partnerships between industrial players, in this region. Furthermore, companies like Thermos Fisher Scientific and Illumina are expanding their partnerships with Asian industrial leaders for product expansion.
The “Next Generation Sequencing Market (2nd Edition): Industry Trends and Global Forecasts, till 2035” market report features an extensive study of the current market landscape of NGS service providers, market landscape of next-generation sequencing technologies, technologies / platform competitive analysis, patent analysis, clinical trial analysis, big pharma analysis, case study on NGS initiatives sponsored by government, and market size and future opportunities within the next generation sequencing industry, during the forecast period. The market report highlights the efforts of several stakeholders engaged in this rapidly emerging market segmentation of the pharmaceutical industry. Key takeaways of the market report have been briefly discussed below.
Currently, the NGS market landscape features more than 10 companies claiming to provide an extensive portfolio of sequencers. Notably, the key players of the industry have developed a wide range of gene sequencing systems including next generation technologies that have the capability to sequence entire genomes with higher accuracy. Some of the prominent players who have developed sequencers include Illumina, Thermo Fisher Scientific, PacBio and Hoffman La Roche. It is worth highlighting that Ion Torrent ™Genexus™ Dx Integrated Sequencer (Thermo Fisher Scientific), PromethiON™ (Oxford Nanopore Technologies), Ion GeneStudio™ S5 System (Thermo Fisher), iSeq 100 (Illumina) are some of the key next generation sequencing platforms developed in this industry.
The current market landscape also features close to 90 service providers including very large, large, mid-sized and small companies, that claim to have the required expertise to provide services for next-generation sequencing, across different key geographical regions. Notably, 92% of the NGS service providers in the representative dataset offer whole genome sequencing services, followed by whole exome sequencing services (81%) and targeted sequencing (57%). In addition to this, 48% of the next-generation sequencing (NGS) service providers claim to offer all three types of sequencing services.
In order to enhance product portfolio and services, several market leaders are also focused on development of therapeutic drugs based on genetic research. For instance, in March 2024, Psomagen, along with Global Parkinson's Genetics Program (GP2), announced to its plan to conduct whole genome sequencing on nearly 80,000 patients / research payments, that will eventually support in utilizing genetic information for the development of therapeutic strategies for the treatment of Parkinson’s disease. As the research on genomics continues, the demand for next generation sequencing technology will increase in the future, which is anticipated to drive the market during the forecast period.
One of the key drivers of market is the technological advancements and continuous improvements in the next-generation sequencing techniques in order to enhance the efficacy, accuracy and accessibility of next-generation sequencing techniques. Further, in order to mitigate the growing concern of chronic and genetic diseases, leading pharmaceutical players are actively emphasizing the development of more effective next-generation sequencing technologies to ensure accurate analysis of human genome with shorter turnaround time. This ongoing demand to develop advanced next-generation sequencing techniques offer competitive advantage to the leading players, which further helps in the overall growth of the market.
Additionally, the growing focus on non-invasive prenatal testing due to its potential to identify risks associated with genetic disorders, such as down syndrome, cystic fibrosis and sickle cell anemia, has prompted companies to develop cell-free DNA test sequencing kits that are tailored to detect the chromosomal abnormalities at early stages.
In recent years, several biotechnology and pharmaceutical companies have invested extensively in order to evaluate the diagnostic and therapeutic potential of next-generation sequencing. As the demand for next-generation sequencing techniques increases across the globe, the number of clinical trials across different regions is anticipated to increase as well. More than 920 clinical trials related to next-generation sequencing have been registered in the past five years, indicating substantial research in this domain. Among these, about 55% of the clinical trials are actively recruiting patients. This can be attributed to the high disease control rate demonstrated by NGS-guided therapies in various clinical trials, which has eventually encouraged patients to participate in these clinical trials to obtain favorable treatment outcomes.
Since 2020, over 3,060 patents focused on next-generation sequencing have been granted / filed, indicating the substantial efforts made by researchers in this market. It is worth highlighting that majority of the patents (85%) in this domain were patent applications (not having received approval yet), followed by granted patents (14%). Further, it is worth highlighting that majority of the patents in this domain, have been filed by industry players.
The NGS market size for oncological disorders is estimated to be worth USD 4.3 billion in the current year. This can be attributed to the rise in the global incidence rate of genetic and oncological disorders. According to the American Cancer Society, more than 2 million new cancer cases are likely to be reported in the US in 2024. This highlights the need for more effective and targeted sequencing techniques, such as next-generation sequencing, as an effective diagnostic tool to overcome the overall burden of cancer and other genetic disorders.
The next generation sequencing market in 2035 is anticipated to be dominated by the players based in North America (51%) owing to the fact that North America maintains a well-established technology manufacturers network and supportive regulatory guidelines for genome sequencing. Additionally, the advanced healthcare infrastructure and rising focus on oncology precision medicine is another significant driver of the market in this region. Further, 23% market share is anticipated to be captured by the players based in Europe. However, the market in Asia-Pacific is expected to grow at a relatively high CAGR (20.6%), during the forecast period, till 2035.
Next generation sequencing technologies possess the ability to sequence entire genes of an organism, making it a potential tool for clinical research and preclinical studies. Considering the benefits, players active in this region are taking a step forward to develop portable handheld next generation sequencing equipment and platforms, indicating significant opportunities to drive future growth.
The primary objective of developing portable sequencing technologies is to reduce the cost, simplify operation and offer real time analysis. It is worth mentioning that Oxford Nanopore Technologies offer MinION, a handheld DNA / RNA sequencer which can read up to 4Mb of fragment length. Recently, in November 2024, the company announced partnership with the UK government, in order to augment genomics based translational research and utilize its genomics technology in the NHS. Given the growing demand for portable sequencing technologies and growing initiatives to work together with non-industry players, the next generation sequencing market is estimated to grow at a steady rate during the projected period.
Additionally, NGS technologies have been widely integrated with bioinformatics tools, which can support in understanding, interpreting and analyzing the genomics data in a better manner. This also widens opportunities for market players to expand their usage in clinical and epidemiological research. In August 2024, Inocras announced the launch of whole genome sequencing and bioinformatics services that are based on UG 100TM sequencer (developed by Ultima Genomics). As mentioned by Jehee Suh (Chief Executive Officer, Inocras), “Having completed exhaustive feasibility tests, we are ready to offer whole genome sequencing and bioinformatics services on Ultima’s UG 100 system. This enables us to meet diverse needs of our customers in the genomics community with price flexibility. We announced collaboration with Ultima in 2023 with a shared vision to make whole genome insights affordable. That future is already here today”.
Examples of key players in next-generation sequencing industry (which have also been profiled in this market report; the complete list of companies is available in the full report) include Admera Health, Applied Biological Materials, BGI Genomics, CD Genomics, DNA Link, Eurofins Genomics, Gene by Gene, GENEWIZ, Illumina, MedGenome, MGI Tech, Novogene, Oxford Nanopore Technologies, Pacific Biosciences, Psomagen, Thermo Fisher Scientific, Veritas and Xcelris Labs.
The market report presents an in-depth analysis, highlighting the capabilities of various stakeholders in the next-generation sequencing industry, across different geographies. Amongst other elements, the market report includes:
Several recent developments have taken place in the field of next-generation sequencing, some of which have been outlined below. These developments, even if they took place post the release of our market report, substantiate the overall next generation sequencing market trends that we have outlined in our analysis.